Zodasiran Silences Hepatic ANGPTL3 Leading to Deep and Durable Reductions in Atherogenic Lipids and Lipoproteins in Mixed Dyslipidemia Patients: Final Results from Arches-2, Double-Blind Period
Atherosclerosis（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined